[HTML][HTML] Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing …
S Mugusi, E Ngaimisi, M Janabi, F Mugusi… - European Journal of …, 2018 - Springer
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
S Mugusi, E Ngaimisi, M Janabi… - … Journal of Clinical …, 2018 - search.ebscohost.com
Purpose: Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
[PDF][PDF] Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing …
S Mugusi, E Ngaimisi, M Janabi, F Mugusi, O Minzi… - 2018 - researchgate.net
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
S Mugusi, E Ngaimisi, M Janabi, F Mugusi… - European Journal of …, 2018 - europepmc.org
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
S Mugusi, E Ngaimisi, M Janabi, F Mugusi, O Minzi… - 2018 - cabidigitallibrary.org
Purpose: Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
S Mugusi, E Ngaimisi, M Janabi… - … journal of clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
[HTML][HTML] Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing …
S Mugusi, E Ngaimisi, M Janabi, F Mugusi… - European Journal of …, 2018 - ncbi.nlm.nih.gov
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
S Mugusi, E Ngaimisi, M Janabi… - … Journal of Clinical …, 2018 - search.proquest.com
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
[引用][C] Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing …
S Mugusi, E Ngaimisi, M Janabi, F Mugusi… - European Journal of …, 2018 - cir.nii.ac.jp
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based
cART with or without tuberculosis treatment containing rifampicin | CiNii Research CiNii 国立 …
cART with or without tuberculosis treatment containing rifampicin | CiNii Research CiNii 国立 …
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
S Mugusi, E Ngaimisi, M Janabi, F Mugusi… - European Journal of …, 2018 - europepmc.org
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …